| WB | 1/500 - 1/2000 | Human,Mouse,Monkey |
| IF | 咨询技术 | Human,Mouse,Monkey |
| IHC | 咨询技术 | Human,Mouse,Monkey |
| ICC | 技术咨询 | Human,Mouse,Monkey |
| FCM | 1/200 - 1/400 | Human,Mouse,Monkey |
| Elisa | 1/10000 | Human,Mouse,Monkey |
| Aliases | RAL |
| Entrez GeneID | 5898 |
| clone | 4G8B11 |
| WB Predicted band size | 23.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey |
| Immunogen | Purified recombinant fragment of human RALA (AA: 71-203) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于RALA抗体的参考文献示例(注：以下内容为模拟示例，非真实文献)：
---
1. **文献名称**：*"RALA GTPase Mediates Vesicular Trafficking and Chemoresistance in Ovarian Cancer"*
**作者**：Zhang Y, et al.
**摘要**：本研究揭示了RALA通过调控晚期内体运输促进卵巢癌细胞化疗抵抗的机制。研究者使用特异性RALA抗体进行免疫印迹和免疫荧光，证实了RALA在细胞内膜结构的定位，并发现其表达水平与患者预后相关。
2. **文献名称**：*"A Novel Monoclonal Antibody for RALA with Applications in Pancreatic Cancer Diagnosis"*
**作者**：Tanaka K, et al.
**摘要**：团队开发了一种高亲和力的抗RALA单克隆抗体，验证了其在组织切片和血清样本中的特异性。该抗体成功用于ELISA和免疫组化，显示胰腺癌患者中RALA蛋白水平显著升高，提示其作为生物标志物的潜力。
3. **文献名称**：*"RALA Regulates Autophagosome-Lysosome Fusion via Interaction with STX17"*
**作者**：Chen L, et al.
**摘要**：研究通过免疫共沉淀(使用RALA抗体)和基因敲除技术，证明RALA与STX17蛋白相互作用，调控自噬体-溶酶体融合过程，影响细胞代谢稳态，为相关代谢疾病提供了新靶点。
4. **文献名称**：*"Dynamic Localization of RALA in Neuronal Synaptic Vesicles Revealed by Super-Resolution Imaging"*
**作者**：Müller S, et al.
**摘要**：利用特异性RALA抗体结合超分辨显微镜技术，揭示了RALA在神经元突触小泡运输中的动态分布，并发现其磷酸化状态与突触可塑性密切相关。
---
**注**：以上文献为示例性质，实际引用时需查询真实数据库(如PubMed)获取准确信息。如需进一步协助检索真实文献，建议提供更具体的研究方向或关键词。
RALA (RAS-like proto-oncogene A), a member of the RAS GTPase superfamily, plays critical roles in regulating cellular processes such as vesicle trafficking, cytoskeletal organization, and signal transduction. As a small GTPase, it cycles between an active GTP-bound state and an inactive GDP-bound state, acting as a molecular switch to control downstream pathways. Dysregulation of RALA has been implicated in various diseases, including cancer, where its overexpression or hyperactivation promotes tumor progression, metastasis, and therapy resistance.
RALA-specific antibodies are essential tools for studying its expression, localization, and activation dynamics. These antibodies often target distinct epitopes, such as conserved regions or phosphorylation sites (e.g., Ser194), to differentiate between active and inactive states. They enable applications like Western blotting, immunofluorescence, and flow cytometry, aiding in the exploration of RALA's role in cellular contexts. Recent studies also highlight RALA's involvement in neurological disorders and metabolic syndromes, expanding its relevance beyond oncology.
The development of high-affinity, isoform-selective RALA antibodies remains a priority, as cross-reactivity with homologous proteins (e.g., RALB) can complicate data interpretation. Advances in antibody engineering, including monoclonal and phospho-specific variants, continue to enhance precision in both basic research and therapeutic targeting, particularly in personalized medicine approaches for RALA-driven pathologies.
×
